Production (Stage)
Ernexa Therapeutics Inc.
ERNA
$2.29
-$0.08-3.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 365.22% | 755.88% | 1,072.55% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 365.22% | 755.88% | 1,072.55% | -- | -- |
| Cost of Revenue | -85.83% | -59.32% | -4.71% | 584.00% | 394.00% |
| Gross Profit | 478.79% | 389.29% | 466.39% | -260.00% | -164.00% |
| SG&A Expenses | -32.69% | -9.81% | 17.10% | 28.55% | -2.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -30.73% | -14.03% | 2.18% | -4.60% | -19.00% |
| Operating Income | 32.88% | 16.57% | 0.49% | 5.30% | 19.43% |
| Income Before Tax | -101.11% | -105.39% | -125.01% | -10.38% | -11.35% |
| Income Tax Expenses | 950.00% | 1,100.00% | -63.41% | -109.26% | -108.00% |
| Earnings from Continuing Operations | -101.29% | -105.55% | -124.62% | -10.08% | -11.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -101.29% | -105.55% | -124.62% | -10.08% | -11.06% |
| EBIT | 32.88% | 16.57% | 0.49% | 5.30% | 19.43% |
| EBITDA | 33.12% | 16.90% | 0.81% | 5.43% | 19.37% |
| EPS Basic | -46.87% | -79.43% | -98.76% | 21.48% | 28.43% |
| Normalized Basic EPS | 42.10% | 12.61% | -5.31% | 21.90% | -14.66% |
| EPS Diluted | -46.87% | -79.43% | -98.76% | 21.48% | 28.43% |
| Normalized Diluted EPS | 42.10% | 12.61% | -5.31% | 21.90% | -14.66% |
| Average Basic Shares Outstanding | 376.13% | 156.85% | 11.16% | 27.30% | 47.11% |
| Average Diluted Shares Outstanding | 376.13% | 156.85% | 11.16% | 27.30% | 47.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 0.75% | 0.76% | 0.56% | 0.09% | 0.10% |